Jianhong Wu

Fudan University

Papers

1

Total Citations

12

H-Index

1

About

Dr. Jianhong Wu is a leading researcher in urological oncology, with a primary focus on prostate cancer diagnostics and treatment outcomes. His work centers on integrating advanced imaging techniques, particularly MRI fusion biopsy, with clinical risk stratification to improve prognostic accuracy for patients undergoing radical prostatectomy. In his highly cited 2022 study, Dr. Wu developed a novel risk model based on MRI fusion biopsy characteristics to predict biochemical recurrence (BCR) after surgery. By analyzing data from 304 patients, he identified key pre-surgical features that significantly correlate with cancer relapse, offering clinicians a powerful tool to personalize postoperative surveillance and treatment decisions. This contribution has garnered 12 citations, reflecting its immediate relevance in refining BCR prediction beyond traditional parameters. Dr. Wu’s research bridges radiology and surgical oncology, demonstrating how fusion biopsy data can directly inform risk assessment. His work is pivotal for advancing precision medicine in prostate cancer, helping to reduce overtreatment while identifying high-risk patients who may benefit from early adjuvant therapies.

Research Focus

Key Achievements

1
H-Index
1
Papers
12
Total Citations
12
Avg Citations/Paper
🏆 Most Cited Paper
Risk model based on MRI fusion biopsy characteristics predicts biochemical recurrence after radical prostatectomy
12 citations · 2022
📈 Most Prolific Year: 2022 (1 Papers)
🤝 Key Collaborators: 5
🏛 Institutions: Fudan University

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 14 days ago